pharmaphorum July 18, 2024
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances next year.
During the pharma group’s first-half results update, Jennifer Taubert, chair of J&J’s worldwide innovation group, said that it is projecting a “net unfavourable impact” from the negotiations in 2025, but expects growth in other areas of its business to compensate.
Stelara (ustekinumab) is used to treat a range of inflammatory disorders – including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis – and brought in worldwide sales of $5.34 billion in the first half of this year. It will start to face biosimilar competition in Europe...
Today's Sponsors
Today's Sponsor